Compare OESX & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OESX | ELOX |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Building Products | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4M | 43.8M |
| IPO Year | 2007 | N/A |
| Metric | OESX | ELOX |
|---|---|---|
| Price | $10.25 | $11.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $17.50 | N/A |
| AVG Volume (30 Days) | ★ 46.2K | 45.9K |
| Earning Date | 02-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $86,306,000.00 | N/A |
| Revenue This Year | $7.94 | N/A |
| Revenue Next Year | $13.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.26 | N/A |
| 52 Week Low | $0.56 | $10.00 |
| 52 Week High | $18.64 | $15.00 |
| Indicator | OESX | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 48.66 | 37.47 |
| Support Level | $8.60 | $10.51 |
| Resistance Level | $10.38 | $14.50 |
| Average True Range (ATR) | 0.91 | 2.25 |
| MACD | -0.10 | -0.08 |
| Stochastic Oscillator | 31.73 | 25.00 |
Orion Energy Systems Inc provide light emitting diode (LED) lighting systems, wireless Internet of Things (IoT) enabled control solutions, commercial and industrial electric vehicle charging infrastructure solutions and lighting and electrical maintenance services. It help its customers achieve their sustainability, energy savings and carbon footprint reduction goals through technology and exceptional service. It sell its products and services into many vertical markets within the broader commercial and industrial market segment. Primary verticals include box retail, manufacturing, warehousing/logistics, federal and municipal government, healthcare and schools. It has three segments Lighting, Maintenance, and EV segment. It generates majority of revenue from Lighting segment.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.